Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3343596rdf:typepubmed:Citationlld:pubmed
pubmed-article:3343596lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:3343596lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3343596lifeskim:mentionsumls-concept:C0035179lld:lifeskim
pubmed-article:3343596lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:3343596lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3343596lifeskim:mentionsumls-concept:C1156510lld:lifeskim
pubmed-article:3343596lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:3343596lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:3343596pubmed:issue1lld:pubmed
pubmed-article:3343596pubmed:dateCreated1988-3-28lld:pubmed
pubmed-article:3343596pubmed:abstractTextThe clinical and biochemical effects of adjuvant reserpine treatment were investigated in 12 chronic schizophrenic patients on long-term neuroleptic medication. The global severity of the symptoms using the Brief Psychiatric Rating Scale did not change significantly in the whole group, however, a moderate decrease in positive symptoms (factors though disturbance, activation and hostile-suspiciousness) was observed for 5 patients. Cerebrospinal fluid (CSF) noradrenaline levels showed a consistent decrease, but other biochemical parameters (CSF dopamine metabolites, platelet MAO and serum dopamine-beta-hydroxylase activities) did not change significantly. The changes of clinical symptoms and biochemical parameters did not show any correlation.lld:pubmed
pubmed-article:3343596pubmed:languageenglld:pubmed
pubmed-article:3343596pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3343596pubmed:citationSubsetIMlld:pubmed
pubmed-article:3343596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3343596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3343596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3343596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3343596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3343596pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3343596pubmed:statusMEDLINElld:pubmed
pubmed-article:3343596pubmed:issn0300-9564lld:pubmed
pubmed-article:3343596pubmed:authorpubmed-author:MagyarKKlld:pubmed
pubmed-article:3343596pubmed:authorpubmed-author:SeregiAAlld:pubmed
pubmed-article:3343596pubmed:authorpubmed-author:FeketeM IMIlld:pubmed
pubmed-article:3343596pubmed:authorpubmed-author:BelfDDlld:pubmed
pubmed-article:3343596pubmed:authorpubmed-author:AratoMMlld:pubmed
pubmed-article:3343596pubmed:authorpubmed-author:BagdyGGlld:pubmed
pubmed-article:3343596pubmed:authorpubmed-author:PerenyiAAlld:pubmed
pubmed-article:3343596pubmed:authorpubmed-author:FrecskaEElld:pubmed
pubmed-article:3343596pubmed:authorpubmed-author:TothfalusiLLlld:pubmed
pubmed-article:3343596pubmed:issnTypePrintlld:pubmed
pubmed-article:3343596pubmed:volume71lld:pubmed
pubmed-article:3343596pubmed:ownerNLMlld:pubmed
pubmed-article:3343596pubmed:authorsCompleteYlld:pubmed
pubmed-article:3343596pubmed:pagination73-8lld:pubmed
pubmed-article:3343596pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:meshHeadingpubmed-meshheading:3343596-...lld:pubmed
pubmed-article:3343596pubmed:year1988lld:pubmed
pubmed-article:3343596pubmed:articleTitleEffect of adjuvant reserpine treatment on catecholamine metabolism in schizophrenic patients under long-term neuroleptic treatment.lld:pubmed
pubmed-article:3343596pubmed:affiliationNational Institute for Nervous and Mental Diseases, Budapest, Hungary.lld:pubmed
pubmed-article:3343596pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3343596pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed